Skip to main content
. Author manuscript; available in PMC: 2024 Jan 11.
Published in final edited form as: Nat Rev Rheumatol. 2021 Jun 29;17(8):462–474. doi: 10.1038/s41584-021-00637-8

Table 1 ∣.

Limitations of CRISPR-Cas editing systems

Application Genomic editing technique Advantages Disadvantages
Identifying and investigating autoimmune-associated loci and genes CRISPR–Cas-mediated genome wide screening30-34 All annotated genes can be targeted Limited to cell lines
Can discover cell type-specific effects Requires a functional outcome (for example, proliferation)
CRISPR–Cas-mediated knockout of individual genes37,38 Function can be assessed Low throughput
Amenable to primary immune cells
CRISPR–Cas-mediated activation (CRISPRa) or interference (CRISPRi) of gene expression61,64 Easily multiplexable Currently limited to cell lines
Identifying autoimmune regulatory regions CRISPR–Cas-mediated activation (CRISPRa) or interference (CRISPRi) of regulatory region60,62,63,65 Can test any region of the genome Effects might be context-dependent and require multiple cell lines for verification
CRISPR–Cas-mediated deletion or mutagenesis of regulatory regions55
Identifying causal variants CRISPR–Cas-mediated mutagenesis of causal variants58 Amenable to primary immune cells Induced deletions, insertions and substitutions are random and do not recapitulate variant changes
Some variants cannot be directly targeted
CRISPR–Cas-mediated homology directed repair80,83 Can directly change reference allele to an alternative allele Bystander mutations
CRISPR–Cas-mediated base editing85-90 Not all mutations are possible
CRISPR–Cas-mediated prime editing91 Low efficiency
Linking variants to causal immune cell types CRISPR–Cas-mediated editing paired with single-cell technologies101-105 Can be used to directly identify cell populations of interest in rheumatic disorders Expensive and prone to drop-out in gene expression
Can assess the function of a particular variant in a broad range of cell populations simultaneously